‘Lithuania Pharmaceuticals and Healthcare Report Q2 2008’ Reveals Forecasts for the Coming Five Years Annual Growth at Single-Digit Figures

DUBLIN, Ireland–(EMWNews)–Research and Markets (http://www.researchandmarkets.com/research/644948/lithuania_pharmace)

has announced the addition of the “Lithuania Pharmaceuticals and

Healthcare Report Q2 2008” report to their offering.

The Lithuania Pharmaceuticals and Healthcare Report provides independent

forecasts and competitive intelligence on Lithuania’s pharmaceuticals

and healthcare industry.

While larger than its Baltic counterparts in terms of value, the

Lithuanian pharmaceutical market remains one of the smallest in the

Central and Eastern European (CEE) region. Despite strong recent growth

– 14% year-on-year (y-o-y) for the three months February through to

April 2007, according to distributor Tamro – funding pressures and

out-of-pocket spending on drugs, limited by patient purchasing power

leads BMI to forecasts for the coming five years annual growth at

single-digit figures. Market growth is also contingent on the country’s

fractious parliament and current weak government managing to steward the

fast-growing economy, or fresh elections yielding more workable

arrangements before the next round of scheduled parliament polls in

October 2008.

In the meantime, the country’s creaking public

services – in particular healthcare – require urgent attention, despite

the attempts of successive governments to develop a modern primary

sector, with doctors providing a gatekeeper function to specialists.

While the President appears committed to reducing corruption, power

struggles and appeals to populism are blamed for preventing movement on

badly needed economic and social reforms. However, although the

fractious political scene threatens to derail the much-needed reforms,

the new multiparty governing coalition has put forward a platform based

on investment in social services.

In the adjusted BMI‘s Business Environment

Rankings for the 16 major CEE markets, Lithuania is once again ranked

joint twelfth, alongside Croatia. While Lithuania’s

strong economic growth and surging levels of consumer spending are

stimulating pharmaceutical market growth, economic and political risks

remain a cause for concern. The fact that the country’s

drug-manufacturing sector is small and export-oriented illustrates

limited long-term market potential for foreign-made products.

Nevertheless, imports will continue to provide the bulk of patented

medicines, the demand for which is rising with healthcare modernization

and improvement of patient awareness.

In February 2008, police opened an investigation into the potential

health hazards of a psychoactive herb – Salvia divinorum – sold on the

internet in Lithuania. Law enforcement agencies are aiming to assess its

sale through such channels, with a view to banning it. The usage of the

herb, which originates in Mexico, is not regulated by EU authorities.

The issue also highlights the problems facing cross-border trade in

pharmaceuticals and herbal medicines in the face of expanding use of

internet and other sales channels.

Key Topics Covered:

Executive Summary

Lithuania Pharmaceuticals and Healthcare Industry SWOT

Political SWOT

Economic SWOT

Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Central and Eastern Europe Pharmaceutical Business Environment

Rankings

Limits of Potential ReturnsRisk To Realization Of Returns

Lithuania – Market Summary

Regulatory Regime

Recent Regulatory Developments

Intellectual Property Developments

USTR “Special 301” Report

Pricing Regime

Reimbursement Regime

Industry Developments

Epidemiology

Table: Selected Health Indicators For Lithuania, 1995-2005

Healthcare System

Table Healthcare Facilities And Personnel In Lithuania, 1995-2005

Healthcare Funding

Healthcare Insurance

Corruption

Pharmaceutical Industry

Table: Drugmakers, Distributors And Retailers Active In The Baltic

States, Q207

Recent Pharmaceutical Industry Developments

Wholesale

Retail

Biotechnology

Medical Devices

Industry Forecast Scenario

Overall Market Forecast

Table: Lithuania’s Drug Expenditure and

Prescription Market Indicators, 2006-2012 (US$mn unless otherwise stated)

Key Growth Factors – Industry

Table: Lithuania’s Healthcare Expenditure

Forecast Indicators

Key Growth Factors – Macroeconomic

Table: Economic Activity

Patented Market Forecast

Table: Lithuania’s Patented Drug Market

Forecast Indicators (US$mn unless otherwise stated)

Generics Market Forecast

Table: Lithuania’s Generics Market

Indicators, 2006-2012 32

OTC Market Forecast

Table: Lithuania’s OTC Market Indicators,

2006-2012 (US$mn unless otherwise stated)

Export/Import Forecasts

Table: Lithuania’s Pharmaceutical Export And

Import Indicators, 2006-2012 (US$mn)

Other Healthcare Data Forecasts

Table: Other Healthcare Data Forecasts

Key Risks To our Forecast Scenario

Competitive Landscape

Company Monitor

Multinational Company Profiles

GlaxoSmithKline

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Indigenous Company Profiles

Valentis

Sanitas

Sicor Biotech

BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

For more information visit http://www.researchandmarkets.com/research/644948/lithuania_pharmace

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions